Athersys Reports Third Quarter 2020 Results and Provides Corporate Update
Athersys, Inc. (NASDAQ: ATHX) reported a net loss of $22.5 million for Q3 2020, compared to a $12 million loss in Q3 2019. Revenue increased to $0.1 million, up from negative $0.4 million the prior year, largely due to collaboration with Healios. Research and development expenses surged to $18.5 million, primarily driven by clinical trial costs. The company has received RMAT designation from the FDA for its MultiStem® treatment for acute respiratory distress syndrome and is advancing clinical trials for COVID-19 and ischemic stroke. Athersys ended the quarter with $61.7 million in cash.
- Received RMAT designation from the FDA for MultiStem® for acute respiratory distress syndrome.
- Commenced Phase 2 clinical trial for MultiStem in trauma-related inflammation.
- Advancing the MACOVIA Phase 2/3 trial for COVID-19 induced ARDS.
- Reactived clinical sites for MASTERS-2 ischemic stroke study.
- Collaboration revenue increased, indicating progress with Healios.
- Net loss increased to $22.5 million in Q3 2020 from $12 million in Q3 2019.
- Research and development expenses rose significantly to $18.5 million.
- Cash used in operating activities increased to $44.5 million in the first nine months of 2020.
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three months ended September 30, 2020 and provided a corporate update.
Highlights of the third quarter of 2020 and recent events include:
- Received Regenerative Medicine Advanced Therapy (RMAT) designation for MultiStem® from the U.S. Food and Drug Administration (FDA) for the treatment of acute respiratory distress syndrome (ARDS), a designation enabling additional interactions with the FDA that are focused on expediting development;
- Commenced patient screening for the Phase 2 clinical trial led by The University of Texas Health Science Center at Houston (UTHealth) evaluating MultiStem Administration for Trauma Related Inflammation and Complications (MATRICS-1) in patients at Memorial Hermann-Texas Medical Center, a leading Level 1 Trauma center;
- Further advanced the MACOVIA Phase 2/3 trial evaluating MultiStem administration to patients with COVID-19 induced ARDS and advanced preparations to potentially expand the study to include a broader range of patients with ARDS, including from influenza and other pathogens;
- Advanced the MASTERS-2 ischemic stroke study, reactivating all clinical sites previously impacted by COVID-19 operational disruptions, and adding new sites to the study;
- Received notification that HEALIOS K.K. (Healios), our Japanese partner, completed enrollment of its COVID-19 induced ARDS patient cohort in its ONE-BRIDGE study. Healios has previously stated it intends to complete enrollment of the entire ONE-BRIDGE study and the TREASURE ischemic stroke study by around the end of the year;
- Advanced our partnering negotiations regarding MultiStem for potential commercialization in Europe and other regions of interest;
- Continued key initiatives for establishing commercialization readiness, including supply chain and logistics, process development, manufacturing, branding and other key areas;
-
Recognized net loss of
$22.5 million , or$0.11 net loss per share, for the quarter ended September 30, 2020; and -
Ended the third quarter with
$61.7 million of cash and cash equivalents.
“Despite the continuing chaos created by the ongoing COVID-19 pandemic, we made excellent progress this quarter. Our clinical programs and ongoing partnering negotiations continue to advance, and our efforts to establish commercial readiness in several key areas have also made good progress,” commented Dr. Gil Van Bokkelen, Chairman and CEO of Athersys. “We have maintained a strong financial position while also continuing to build key capabilities that would support our planned transition into commercialization following regulatory approval of our innovative therapies.
“Completing a high value partnership for Europe and potentially other geographies is an important near-term priority, and we are focused on achieving that goal, which will be a key event in the continued evolution of the company,” concluded Dr. Van Bokkelen.
Third Quarter Results
There were revenues of
Research and development expenses increased to
General and administrative expenses increased to
Net loss for the third quarter of 2020 was
During the nine months ended September 30, 2020, net cash used in operating activities was
Conference Call
Gil Van Bokkelen, Chairman and Chief Executive Officer, Ivor Macleod, Chief Financial Officer, and Karen Hunady, Director of Corporate Communications and Investor Relations will host a conference call today to review the results as follows:
Date |
|
November 9, 2020 |
Time |
|
4:30 p.m. (Eastern Time) |
Live webcast registration |
|
|
Phone registration |
|
We encourage shareholders to listen using the webcast link above. If you would like to dial in using the phone to ask a question, please register for the conference call ahead of time using the call registration link above. Once registered, you will receive the toll-free number, a direct entry passcode and a registrant ID.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived “off-the-shelf” stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These forward-looking statements relate to, among other things, the expected timetable for development of our product candidates, our growth strategy, and our future financial performance, including our operations, economic performance, financial condition, prospects, and other future events. We have attempted to identify forward-looking statements by using such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “should,” “suggest,” “will,” or other similar expressions. These forward-looking statements are only predictions and are largely based on our current expectations. A number of known and unknown risks, uncertainties, and other factors could affect the accuracy of these statements. Some of the more significant known risks that we face are the risks and uncertainties inherent in the process of discovering, developing, and commercializing products that are safe and effective for use as therapeutics, including the uncertainty regarding market acceptance of our product candidates and our ability to generate revenues. The following risks and uncertainties may cause our actual results, levels of activity, performance, or achievements to differ materially from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements: our ability to raise capital to fund our operations, including but not limited to, our ability to access our traditional financing sources on the same or reasonably similar terms as were available to us before the COVID-19 pandemic; the timing and nature of results from MultiStem clinical trials, including the MASTERS-2 Phase 3 clinical trial evaluating the administration of MultiStem for the treatment of ischemic stroke, and the Healios TREASURE and ONE-BRIDGE clinical trials in Japan evaluating the treatment in stroke and ARDS patients, respectively; the success of our MACOVIA clinical trial evaluating the administration of MultiStem for the treatment of COVID-19 induced ARDS, and the MATRICS-1 clinical trial being conducted with The University of Texas Health Science Center at Houston evaluating the treatment of patients with serious traumatic injuries; the impact of the COVID-19 pandemic on our ability to complete planned or ongoing clinical trials; the possibility that the COVID-19 pandemic could delay clinical site initiation, clinical trial enrollment, regulatory review and potential receipt of regulatory approvals, payments of milestones under our license agreements and commercialization of one or more of our product candidates, if approved; the availability of product sufficient to meet commercial demand shortly following any approval, such as in the case of accelerated approval for the treatment of COVID-19 induced ARDS; the impact on our business, results of operations and financial condition from the ongoing and global COVID-19 pandemic, or any other pandemic, epidemic or outbreak of infectious disease in the United States; the possibility of delays in, adverse results of, and excessive costs of the development process; our ability to successfully initiate and complete clinical trials of our product candidates; the impact of the COVID-19 pandemic on the production capabilities of our contract manufacturing partners and our MultiStem trial supply chain; the possibility of delays, work stoppages or interruptions in manufacturing by third parties or us, such as due to material supply constraints, contamination, operational restrictions due to COVID-19 or other public health emergencies, labor constraints, regulatory issues or other factors which could negatively impact our trials and the trials of our collaborators; uncertainty regarding market acceptance of our product candidates and our ability to generate revenues, including MultiStem cell therapy for neurological, inflammatory and immune, cardiovascular and other critical care indications; changes in external market factors; changes in our industry’s overall performance; changes in our business strategy; our ability to protect and defend our intellectual property and related business operations, including the successful prosecution of our patent applications and enforcement of our patent rights, and operate our business in an environment of rapid technology and intellectual property development; our possible inability to realize commercially valuable discoveries in our collaborations with pharmaceutical and other biotechnology companies; our ability to meet milestones and earn royalties under our collaboration agreements, including the success of our collaboration with Healios; our collaborators’ ability to continue to fulfill their obligations under the terms of our collaboration agreements and generate sales related to our technologies; the success of our efforts to enter into new strategic partnerships and advance our programs, including, without limitation, in North America, Europe and Japan; our possible inability to execute our strategy due to changes in our industry or the economy generally; changes in productivity and reliability of suppliers; the success of our competitors and the emergence of new competitors; and the risks mentioned elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2019 under Item 1A, “Risk Factors” and our other filings with the SEC. You should not place undue reliance on forward-looking statements contained in this press release, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.
(Tables Follow)
Athersys, Inc. Condensed Consolidated Balance Sheets (In thousands) |
||||||||
|
|
September 30,
|
|
December 31,
|
||||
|
|
(Unaudited) |
|
(Note) |
||||
Assets |
|
|
|
|
||||
Cash and cash equivalents |
|
$ |
61,711 |
|
|
$ |
35,041 |
|
Accounts receivable |
|
— |
|
|
17 |
|
||
Accounts receivable from Healios |
|
141 |
|
|
945 |
|
||
Prepaid expenses, deposits and other |
|
3,942 |
|
|
2,781 |
|
||
Equipment, net |
|
3,069 |
|
|
2,882 |
|
||
Total assets |
|
$ |
68,863 |
|
|
$ |
41,666 |
|
Liabilities and stockholders’ equity |
|
|
|
|
||||
Accounts payable, accrued expenses and other |
|
$ |
18,230 |
|
|
$ |
11,924 |
|
Accounts payable to Healios |
|
1,205 |
|
|
1,068 |
|
||
Deferred revenue - Healios |
|
65 |
|
|
65 |
|
||
Advance from Healios |
|
5,201 |
|
|
5,338 |
|
||
Total stockholders' equity |
|
44,162 |
|
|
23,271 |
|
||
Total liabilities and stockholders' equity |
|
$ |
68,863 |
|
|
$ |
41,666 |
|
Note: The Condensed Consolidated Balance Sheet Data has been derived from the audited financial statements as of that date.
Athersys, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (In Thousands, Except Per Share Amounts) |
||||||||
|
|
Three months ended
|
||||||
|
|
2020 |
|
2019 |
||||
Revenues |
|
|
|
|
||||
Contract revenue from Healios |
|
$ |
85 |
|
|
$ |
(368) |
|
Grant revenue |
|
1 |
|
|
7 |
|
||
Total revenues |
|
86 |
|
|
(361) |
|
||
Costs and expenses |
|
|
|
|
||||
Research and development |
|
18,471 |
|
|
8,856 |
|
||
General and administrative |
|
3,700 |
|
|
2,958 |
|
||
Depreciation |
|
233 |
|
|
167 |
|
||
Total costs and expenses |
|
22,404 |
|
|
11,981 |
|
||
Loss from operations |
|
(22,318) |
|
|
(12,342) |
|
||
Other (expense) income, net |
|
(225) |
|
|
327 |
|
||
Net loss and comprehensive loss |
|
$ |
(22,543) |
|
|
$ |
(12,015) |
|
Net loss per share, basic and diluted |
|
$ |
(0.11) |
|
|
$ |
(0.08) |
|
Weighted average shares outstanding, basic and diluted |
|
197,343 |
|
|
153,096 |
|
||
